Contact us
  • Detect Early

    DX ICDs increase the likelihood of detecting atrial arrhythmias early compared to single-chamber ICDS,¹ helping you to identify patients at risk and enabling prompt, appropriate patient management.

  • Monitor Reliably

    DX Technology allows you to assess and reliably monitor² AF burden as well as subsequent disease progression over time.

  • Improve Outcomes

    Since DX Technology can detect and monitor AF burden, appropriate therapy can be initiated in a timely manner for improved clinical outcomes.3,4

Detect Early

DX ICDs increase the likelihood of detecting atrial arrhythmias early compared to single-chamber ICDS,¹ helping you to identify patients at risk and enabling prompt, appropriate patient management.

Only DX Technology combines a single tachy lead with the ability to offer direct atrial sensing in ICD patients. Combined with BIOTRONIK Home Monitoring®, DX Technology provides device diagnostics in a timely manner, allowing physicians to detect atrial arrhythmias early.¹

  • DX provides a direct, true atrial signal thanks to the DX lead enhanced with a floating atrial dipole.
  • DX is proven to provide long-term stable atrial sensing (24-month follow-up period).1,2,7
  • The DX ICD is nearly four times more likely to detect subclinical AF than with a standard single-chamber ICD in patients without a history of atrial arrhythmias at implant.1,7
  • DX ICDs have shown superior AHRE detection rates compared to traditional single chamber ICDs, and equivalent detection rates to dual-chamber ICDS (AHRE detection rates: DX: 13%, VR-ICD: 5.3%, DR-ICD: 13%)¹

Monitor Reliably

DX Technology allows you to assess and reliably monitor² AF burden as well as subsequent disease progression over time.

Once AF is detected, quantification of AF burden becomes critically important for timely intervention, supported by the AHA/ACC/HRS and European Society of Cardiology (ESC) guidelines on AF management.3,4 Because of its unique atrial sensing capabilities and comprehensive diagnostics, the DX ICD system correctly classifies atrial arrhythmias and quantifies AHRE burden.

Remote monitoring with AHRE alerts increases the likelihood of detecting silent AF.”
– AHA/ACC/HRS Guidelines4
  • DX allows for a correct estimation of AF burden with reliable classification of AHRE episodes by their duration²
  • DX helps healthcare professionals adhere to the AHA/ACC/HRS and ESC guidelines on AHRE monitoring and initiate OAC treatment for stroke prevention in a timely manner3,4

Improve Outcomes

Since DX Technology can detect and monitor AF burden, appropriate therapy can be initiated in a timely manner for improved clinical outcomes.3,4

The early detection and reliable monitoring of AHRE episodes can provide the diagnostic information needed to inform intervention strategies. Atrial diagnostics provided by DX have led to a variety of therapeutic interventions across multiple studies.2,7,8

  • When AF burden becomes significant in DX ICD patients, the most common intervention is prescribing OAC.7
  • In the THINGS study, incidence of OAC onset was twice as high in the DX group compared to the traditional single-chamber ICD group.7
  • In the REACT DX study, 69% of DX patients with no history of AF and new-onset AHRE detection had OAC initiated within an average of 24 days.8

Clinical Evidence

More Than a Decade of Clinical Experience

DX Technology is supported by a vast body of clinical evidence. Since 2009, more than 100,000 implantations5 have been performed in more than 80 countries,5 supported by more than 20 clinical studies involving more than 4,000 patients.6
This strong foundation of clinical evidence has recently been enriched by the MATRIX study results, the largest clinical evaluation of DX Technology to date.²

>100,000 DEVICES IMPLANTED
>4,000 PATIENTS STUDIED
>20 CLINICAL STUDIES

Resource Library

Content title 01

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris id condimentum odio. File Type

Video title 02

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris id condimentum odio. File Type

Content title 03

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris id condimentum odio. File Type

Content title 04

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris id condimentum odio. File Type

Video title 05

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris id condimentum odio. File Type

Content title 06

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris id condimentum odio. File Type

Content title 07

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris id condimentum odio. File Type

Video title 08

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris id condimentum odio. File Type

Contact us

  • Thomas G, et al. Subclinical atrial fibrillation detection with a floating atrial sensing dipole in single lead implantable cardioverter-defibrillator systems: Results of the SENSE trial. Journal of Cardiovascular Electrophysiology, Volume 30, Issue 10, October 2019, Pages 1994–2001.
  • Hindricks G, Theuns DA, Bar-Lev D, et al. Ability to remotely monitor atrial high-rate episodes using a single-chamber implantable cardioverter-defibrillator with a floating atrial sensing dipole. EP Europace, 2023, 00, 1-10.
  • Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, Volume 42, Issue 5, 1 February 2020, Pages 373–498.
  • January C, Wann LS, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;140:e125-e151.
  • Data on file, as of January 2024.
  • Based on completed studies with a focus on DX Technology. Further DX recipients are included in ongoing studies or studies with broader scope.
  • Biffi M, Iori M, De Maria E, et al. The role of atrial sensing for new-onset atrial arrhythmias diagnosis and management in single-chamber implantable cardioverter-defibrillator recipients: Results from the THINGS registry. Journal of Cardiovascular Electrophysiology, Volume 31, Issue 4, April 2020, Pages 846–853.
  • O’Connor M, et al. “REACT DX Registry: Real world reaction to atrial high-rate episodes detected in implantable cardioverter-defibrillator recipients with a DX lead” Technology And Health Care 2023;31:735-746